Wegovy weight loss in the first month: what clinical evidence actually shows

What STEP 1 recorded in the early weeks, and why month one looks modest

The STEP 1 trial is the most cited source on Wegovy's effectiveness, and its data makes one thing clear: meaningful weight loss on semaglutide is a gradual process. Participants lost around 2–4% of their starting weight in the first four weeks, which is worth bearing in mind when you read about what semaglutide one month results typically look like across different patient groups. By week 20 the average had climbed to roughly 9%. By week 68 it reached approximately 15%. Those three numbers together tell you more than any single figure can: the medicine's effect compounds as the dose rises and as the body's appetite signals recalibrate over months, not days.

That early modesty is by design rather than by failure. The starting dose of 0.25 mg (confirmed in the NHS patient information for semaglutide) exists to let your digestive system adjust. It is a settling dose, not the therapeutic one. Expecting significant fat loss in week one is a bit like expecting a new exercise habit to change your physique before you have broken a sweat three times. The mechanism needs time, and the dose needs to rise before it reaches full effect.

This is a question our prescribers hear most weeks: "I've been on it a month and I've only lost a kilogram, is something wrong?" The honest answer, most of the time, is no. A kilogram in month one at the starter dose is consistent with the trial data. The trajectory matters more than the snapshot.

How the dose schedule shapes what you see in month one

Wegovy's titration pathway runs from 0.25 mg through 0.5 mg, 1.0 mg and 1.7 mg, up to the standard 2.4 mg maintenance dose, with each step taking approximately four weeks. The MHRA has also approved a 7.2 mg dose in a dedicated pen, approved in April 2026, though that is the upper end of a long journey for established patients. You can read more about how the full schedule unfolds on our page covering how long Wegovy takes to work.

For the first month specifically, the clinical picture is shaped by two things happening at once. First, the appetite-suppressing effect is present but partial at 0.25 mg. Second, side effects, principally nausea, vomiting and loose stools, tend to peak during this period and can make eating feel unappealing in ways that are not purely pharmacological. Some of what looks like appetite suppression early on is partly tolerability. As the weeks pass and the body adjusts, the GI symptoms typically ease, the dose rises and the appetite reduction becomes steadier and more pronounced.

People also vary enormously. Body weight, baseline metabolic rate, adherence to the lifestyle changes recommended alongside treatment and individual sensitivity to semaglutide all pull in different directions. Two people starting on the same day may have genuinely different month-one outcomes, and if you want to understand the range of experiences, our page on one month Wegovy results goes into the detail of what that spread actually looks like. Comparing your progress only to trial averages, or to someone else's experience, is rarely useful. Detailed breakdowns of one-month results data can help frame what range is realistic rather than what a single number implies.

Side effects in month one: what to expect and when to take them seriously

GI symptoms are the dominant experience for many people in the first four weeks. Nausea is reported by roughly half of Wegovy users, most prominently in the early weeks and after each dose step. Vomiting, diarrhoea, constipation, reflux and fatigue appear less consistently but are not uncommon. These effects are dose-dependent, which is exactly why the titration schedule exists. Most settle within a week or two of each new dose.

Practical steps that can reduce discomfort include eating slowly, choosing smaller portions, keeping meals lower in fat during the adjustment period, and staying well hydrated. None of those replace prescriber or pharmacist guidance, and the Patient Information Leaflet that comes with your pen covers them in detail.

Two situations call for prompt medical attention. Severe, persistent abdominal pain that radiates towards the back could indicate pancreatitis, which the MHRA flagged as a known but infrequent risk in a safety communication in January 2026, get medical help the same day if that describes your pain. Signs of a serious allergic reaction, difficulty breathing or facial swelling also require immediate care. You can report any suspected side effect through the MHRA Yellow Card scheme. For a broader look at how Wegovy's side-effect profile compares across the full course of treatment, our Wegovy treatment overview covers this in more depth.

How to read your own month-one progress honestly

The temptation to judge a medicine's worth against its first four weeks is understandable. It is also, for Wegovy, almost always too early. The trial data is unambiguous that the largest share of weight loss occurs between roughly weeks 8 and 44. Month one is the foundation: adjusting to the medication, establishing the habit, tolerating the starter dose.

A few practical reference points are worth keeping in mind. Loss of around 0.5–2 kg in the first month is broadly consistent with what trials recorded, depending on starting weight and individual response. Visible or measurable change often lags behind what is happening internally, including changes in blood pressure, blood glucose and inflammatory markers, some of which begin shifting before the scale does. And the lifestyle component matters: semaglutide was trialled alongside a reduced-calorie diet and increased physical activity. The medicine amplifies those efforts; it does not replace them.

If you are weighing up the cost of private treatment against what month one looks like, our Wegovy pricing page sets out what a transparent, all-in price from a GPhC-registered pharmacy actually includes. No subscription, no hidden fees, but do read it with the timeline in mind. The full case for treatment is built over months, not weeks. When you are ready to talk it through properly, speaking to our prescribers is the natural next step.